Actinidia eriantha Polysaccharide and PD1-Antibody Combination Therapy Enhances Antitumor Efficacy in Colorectal Cancer–Xenograft Mice
Authors Li J, Wang Y, Jin W, Shen L
Received 30 November 2020
Accepted for publication 5 February 2021
Published 24 February 2021 Volume 2021:14 Pages 1239—1248
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Leo Jen-Liang Su
Jinxia Li,1 Yiping Wang,2 Weiyang Jin,3 Li Shen4
1College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, 410208, People’s Republic of China; 2Key Laboratory of Digestive Pathophysiology of Zhejiang Province, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, People’s Republic of China; 3School of Life and Environmental Science, Hangzhou Normal University, Hangzhou, 311121, People’s Republic of China; 4Institute of Basic Theory of TCM, China Academy of Chinese Medical Sciences, Beijing, 100700, People’s Republic of China
Correspondence: Li Shen
Institute of Basic Theory of TCM, China Academy of Chinese Medical Sciences, Beijing, 100700, People’s Republic of China
Objective: To observe the efficacy of Actinidia eriantha polysaccharide (AEPS) combined with PD1 antibody therapy in colorectal cancer–xenograft mice.
Methods: CT26 cells were inoculated into 80 C57BL/6 mice to establish the colorectal cancer xenograft–mouse model. Mice were divided evenly into a model group, AEPS group, anti-PD1 group, and combined group. AEPS 5mL/kg•day was given orally and 10 mg/kg anti-PD1 injected intravenously for 28 days. Tumor growth and mouse survival were observed. Tumor-cell proliferation and metastasis markers Ki67, N-cadherin, KLF4, and Oct4 were detected with immunochemistry and Western blotting, T-cell infiltration in spleens and tumors was detected with MTT and flow cytometry. IFNγ and TNFα were detected with ELISA.
Results: Tumor growth was significantly retarded and survival prolonged in the AEPS, anti-PD1, and combined groups. Ki67 expression decreased in the anti-PD1 and combined groups, and N-cadherin, KLF4, and Oct4 expression decreased in the AEPS and combined groups. IFNγ and TNFα levels, T-cell infiltration in spleen, and tumor all increased distinctively in the AEPS and combined groups. The combined group showed better antitumor effects and life-extension effect than the other two groups.
Conclusion: AEPS and PD1 antibody-combination therapy can suppresses tumor growth and prolong survival of colorectal cancer–xenograft mice by regulating immunofunction, and the combined therapy showed better therapeutic efficacy than the single treatment.
Keywords: colorectal cancer, PD1 antibody, Actinidia eriantha polysaccharide, combined therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]